当前位置： SCI文献检索 > GYNECOLOGIC ONCOLOGY期刊下所有文献 > Cost-effectiveness of adding bevacizumab to first line therapy for patients with advanced ovarian cancer.

Cost-effectiveness of adding bevacizumab to first line therapy for patients with advanced ovarian cancer.

Abstract：

OBJECTIVE:To evaluate, from a societal perspective, the cost-effectiveness of adding bevacizumab to first-line therapy based on outcomes from the GOG-218 and ICON-7 trials. METHODS:A three-state Markov model was used. The time horizon was until the death of 99% of the initial cohort of 1000 individuals. Costs and quality-adjusted life-years (QALYs) were discounted at an annual rate of 3%. All costs were adjusted to 2013 USD. The incremental cost-effectiveness ratio (ICER) was reported as incremental cost per QALY gained. The robustness of the result was checked with one-way sensitivity analyses and for relevant clinical situations (i.e. varying the drug of choice to treat cancer recurrence). Subgroup analysis was conducted to identify subgroup of population for whom the strategy could be cost-effective. The potential impact of biosimilar bevacizumab was considered, using a 30% price reduction. RESULTS:For the GOG-218 study protocol, widely followed in US, the addition of bevacizumab results in an ICER of $2,420,691/QALY. For the ICON-7 study protocol, the ICER is $225,515/QALY. The results of the model were sensitive to the quality of life (QoL) and the median progression free survival (PFS). Biosimilar bevacizumab didn't reduce cost sufficiently to change conclusions. First-line augmentation is cost-effective, with biosimilar bevacizumab, for stage IV patients ($126,169/QALY), ECOG PS1 patients ($116,575/QALY) and for patients with suboptimal residual disease ($122,822/QALY) as per the ICON-7 protocol. CONCLUSION:Addition of bevacizumab, by in large, is cost-ineffective. It can become cost-effective with the ICON-7 protocol, in patients at high risk of progression using biosimilar bevacizumab.

journal_name

Gynecol Oncol

journal_title

Gynecologic oncology

authors

Mehta DA,Hay JW

doi

10.1016/j.ygyno.2014.01.021

subject

Has Abstract

pub_date

2014-03-01 00:00:00

pages

677-83

issue

3

eissn

0090-8258

issn

1095-6859

pii

S0090-8258(14)00037-7

journal_volume

132

pub_type

杂志文章

相关文献

GYNECOLOGIC ONCOLOGY文献大全
  • Renal ultrasound to detect hydronephrosis: a need for routine imaging after radical hysterectomy?

    abstract：BACKGROUND:Hydronephrosis can be a side effect of radical hysterectomy for cervical cancer. The incidence of clinically relevant hydronephrosis has not been studied in a large sample and the benefit of early detection of hydronephrosis is not clear. OBJECTIVE:To assess the incidence of hydronephrosis, following radica...

    journal_title：Gynecologic oncology

    pub_type： 杂志文章

    doi：10.1016/j.ygyno.2011.09.010

    authors： Hazewinkel MH,Gietelink L,van der Velden J,Burger MP,Stoker J,Roovers JP

    更新日期：2012-01-01 00:00:00

  • Mutations in TAP genes are common in cervical carcinomas.

    abstract：OBJECTIVE:To determine whether squamous cervical cancers exhibit mutations or deletions in MHC class I genes or transport-associated protein (TAP) genes. METHODS:Polymerase chain reaction based protocols were used to examine HLA class I and TAP genes in a panel of cervical tumours, using DNA from corresponding blood s...

    journal_title：Gynecologic oncology

    pub_type： 杂志文章

    doi：10.1016/j.ygyno.2003.11.037

    authors： Fowler NL,Frazer IH

    更新日期：2004-03-01 00:00:00

  • When to Operate, Hesitate and Reintegrate: Society of Gynecologic Oncology Surgical Considerations during the COVID-19 Pandemic.

    abstract：:The COVID-19 pandemic has challenged our ability to provide timely surgical care for our patients. In response, the U.S. Surgeon General, the American College of Srugeons, and other surgical professional societies recommended postponing elective surgical procedures and proceeding cautiously with cancer procedures that...

    journal_title：Gynecologic oncology

    pub_type： 杂志文章,评审

    doi：10.1016/j.ygyno.2020.06.001

    authors： Fader AN,Huh WK,Kesterson J,Pothuri B,Wethington S,Wright JD,Bakkum-Gamez JN,Soliman PT,Sinno AK,Leitao M,Martino MA,Karam A,Rossi E,Brown J,Blank S,Burke W,Goff B,Yamada SD,Uppal S,Dowdy SC

    更新日期：2020-08-01 00:00:00

  • Role of high-risk human papillomavirus (HPV) mRNA testing in the prediction of residual disease after conisation for high-grade cervical intraepithelial neoplasia.

    abstract：OBJECTIVE:To evaluate testing for high-risk human papillomavirus (HR HPV) E6/E7 mRNA transcripts 6 months after conisation for cervical intraepithelial neoplasia grade 2 or worse (CIN2+) to determine the risk of residual CIN2+. METHODS:We prospectively followed 344 women treated for CIN2+ by conisation. HR HPV mRNA te...

    journal_title：Gynecologic oncology

    pub_type： 杂志文章

    doi：10.1016/j.ygyno.2011.07.032

    authors： Tropé A,Jonassen CM,Sjøborg KD,Nygård M,Dahl FA,Alfsen GC,Lie AK

    更新日期：2011-11-01 00:00:00

  • ABC transporter gene expression in benign and malignant ovarian tissue.

    abstract：OBJECTIVE:ATP-binding Cassette (ABC) transporters are thought to cause multiple drug resistance (MDR) in various carcinomas. Gene expression data from individual transporters in ovarian cancer tissue is contradictory and also scarce for some of them. RNA levels of a panel of ABC transporters were collected and analyzed...

    journal_title：Gynecologic oncology

    pub_type： 杂志文章

    doi：10.1016/j.ygyno.2009.10.077

    authors： Auner V,Sehouli J,Oskay-Oezcelik G,Horvat R,Speiser P,Zeillinger R

    更新日期：2010-05-01 00:00:00

  • Intraperitoneal chemotherapy following neoadjuvant chemotherapy and optimal interval tumor reductive surgery for advanced ovarian cancer.

    abstract：OBJECTIVES:Intraperitoneal (IP) chemotherapy following neoadjuvant chemotherapy (NACT) and interval tumor reductive surgery (TRS) for advanced ovarian cancer is feasible, however, the impact on disease outcomes remains unclear. We compare outcomes of patients treated with IP chemotherapy versus intravenous (IV) chemoth...

    journal_title：Gynecologic oncology

    pub_type： 杂志文章

    doi：10.1016/j.ygyno.2019.12.016

    authors： Bixel K,Vetter M,Davidson B,Berchuck A,Cohn D,Copeland L,Fowler JM,Havrilesky L,Lee PS,O'Malley DM,Salani R,Valea F,Alvarez Secord A,Backes F

    更新日期：2020-03-01 00:00:00

  • Endometrial cancer in the oldest old: Tumor characteristics, patterns of care, and outcome.

    abstract：OBJECTIVE:Despite the fact that endometrial cancer commonly occurs in elderly women, little is known about the outcome of the oldest old, those > 80 years of age. We examined the patterns of care and outcome of the oldest old women with endometrial cancer. METHODS:An analysis of women > 65 years of age with endometrio...

    journal_title：Gynecologic oncology

    pub_type： 杂志文章

    doi：10.1016/j.ygyno.2011.02.040

    authors： Wright JD,Lewin SN,Barrena Medel NI,Sun X,Burke WM,Deutsch I,Herzog TJ

    更新日期：2011-07-01 00:00:00

  • Inverse correlation between RASSF1A hypermethylation, KRAS and BRAF mutations in cervical adenocarcinoma.

    abstract：OBJECTIVE:Although the incidence of cervical adenocarcinoma is increasing, few genetic and epigenetic changes in its progression have been described. We hypothesized that RASSF1A methylation and KRAS and BRAF mutations may play an important role in cervical adenocarcinoma. METHODS:Archival primary carcinoma tissues (n...

    journal_title：Gynecologic oncology

    pub_type： 杂志文章

    doi：10.1016/j.ygyno.2007.01.045

    authors： Kang S,Kim HS,Seo SS,Park SY,Sidransky D,Dong SM

    更新日期：2007-06-01 00:00:00

  • Disparities in hospice care among older women dying with ovarian cancer.

    abstract：BACKGROUND:Timely hospice referral is an essential component of quality end-of-life care, although a growing body of research suggests that for patients with various types of cancer, hospice referrals often occur very late in the course of care, and are marked by sociodemographic disparities. However, little is known a...

    journal_title：Gynecologic oncology

    pub_type： 杂志文章

    doi：10.1016/j.ygyno.2011.11.041

    authors： Fairfield KM,Murray KM,Wierman HR,Han PK,Hallen S,Miesfeldt S,Trimble EL,Warren JL,Earle CC

    更新日期：2012-04-01 00:00:00

  • ras oncogene product p21 expression and prognosis of human ovarian tumors.

    abstract：:Monoclonal antibody rp-28 directed against the ras gene product p21 has been studied to evaluate ras p21 expression in malignant and benign ovarian tissues. Some ovarian carcinomas of serous and mucinous cystadenocarcinomas, undifferentiated adenocarcinomas, and clear cell carcinomas demonstrated intense staining of r...

    journal_title：Gynecologic oncology

    pub_type： 杂志文章

    doi：10.1016/0090-8258(92)90194-n

    authors： Yaginuma Y,Yamashita K,Kuzumaki N,Fujita M,Shimizu T

    更新日期：1992-07-01 00:00:00

  • Management of uterine adenosarcomas with and without sarcomatous overgrowth.

    abstract：OBJECTIVES:Uterine adenosarcomas (AS) are rare tumors composed of malignant stromal and benign epithelial components. We sought to evaluate the role of primary surgery, adjuvant treatments, and salvage therapies for patients with uterine adenosarcomas. METHODS:We identified all patients diagnosed with AS from 1990 to ...

    journal_title：Gynecologic oncology

    pub_type： 杂志文章

    doi：10.1016/j.ygyno.2012.12.036

    authors： Tanner EJ,Toussaint T,Leitao MM Jr,Hensley ML,Soslow RA,Gardner GJ,Jewell EL

    更新日期：2013-04-01 00:00:00

  • Phase II study of sequential doublets: topotecan and carboplatin, followed by paclitaxel and carboplatin, in patients with newly diagnosed advanced ovarian cancer.

    abstract：OBJECTIVE:Incorporating topotecan into standard platinum/taxane chemotherapy for advanced ovarian cancer has been complicated by myelosuppression. This study evaluated sequential doublets of topotecan and carboplatin, followed by paclitaxel and carboplatin, in newly diagnosed advanced ovarian cancer patients. METHODS:...

    journal_title：Gynecologic oncology

    pub_type： 临床试验,杂志文章,多中心研究

    doi：10.1016/j.ygyno.2004.05.021

    authors： Gordon AN,Asmar L,Messing MJ,Street DG,Pippitt CH Jr,Bailey CL,Savage J,Young JA

    更新日期：2004-08-01 00:00:00

  • Survival impact of multiple bowel resections in patients undergoing primary cytoreductive surgery for advanced ovarian cancer: a case-control study.

    abstract：OBJECTIVE:To evaluate clinicopathological factors and survival outcome of patients with advanced epithelial ovarian carcinoma undergoing multiple bowel resections to achieve optimal (< or = 1 cm) cytoreduction. METHODS:A case-control study was performed identifying patients undergoing optimal primary cytoreductive sur...

    journal_title：Gynecologic oncology

    pub_type： 杂志文章

    doi：10.1016/j.ygyno.2007.08.003

    authors： Salani R,Zahurak ML,Santillan A,Giuntoli RL 2nd,Bristow RE

    更新日期：2007-12-01 00:00:00

  • Rhabdomyosarcoma of the vagina in a postmenopausal woman: report of a case and review of the literature.

    abstract：:Most rhabdomyosarcomas (RMSs) of the female genital tract occur in infants and young children as sarcoma botryoides. Vaginal RMS occurring in a postmenopausal woman is extremely rare. To our knowledge, only three vaginal RMSs have been reported in patients who were over 50 years of age. Herein, the first case in Taiwa...

    journal_title：Gynecologic oncology

    pub_type： 杂志文章,评审

    doi：10.1006/gyno.1995.1251

    authors： Shy SW,Lee WH,Chen D,Ho SY

    更新日期：1995-09-01 00:00:00

  • Cell proliferation in ovarian carcinoma: superior accuracy of S-phase fraction (SPF) by DNA labeling index versus flow cytometric SPF, lack of independent prognostic power for SPF and DNA ploidy, and limited effect of SPF on tumor growth rate.

    abstract：OBJECTIVES:The goal of this work was to test the hypotheses that S-phase fraction (SPF) by DNA labeling index (SPF-LI) would predict the course of the disease for ovarian/peritoneal carcinomas and that SPF-LI would correlate better with pathologic classification and outcome than SPF by DNA flow cytometry (SPF-F). METH...

    journal_title：Gynecologic oncology

    pub_type： 杂志文章

    doi：10.1006/gyno.2001.6184

    authors： Meyer JS,Gersell DJ,Yim S

    更新日期：2001-06-01 00:00:00

  • Synovial cell sarcoma of the vulva: multimodality treatment incorporating preoperative external-beam radiation, hemivulvectomy, flap reconstruction, interstitial brachytherapy, and chemotherapy.

    abstract：BACKGROUND:Vulvar synovial cell sarcomas are rare, with only four previously published cases in the literature. Traditionally, the primary management for these tumors has been surgery alone. CASE:We report a case of a large vulvar synovial cell sarcoma in a 50-year-old woman treated with comprehensive combined multimo...

    journal_title：Gynecologic oncology

    pub_type： 杂志文章

    doi：10.1016/j.ygyno.2006.09.018

    authors： Holloway CL,Russell AH,Muto M,Albert M,Viswanathan AN

    更新日期：2007-01-01 00:00:00

  • The timing of normalization of CA-125 levels during primary chemotherapy is predictive of survival in patients with epithelial ovarian cancer.

    abstract：OBJECTIVE:To determine if the timing of normalization of CA-125 levels during primary chemotherapy for epithelial ovarian cancer (EOC) could predict survival. METHODS:Patients who reached a complete clinical response for EOC with primary taxane/platinum-based chemotherapy were eligible. Patient demographics, chemother...

    journal_title：Gynecologic oncology

    pub_type： 杂志文章

    doi：10.1016/j.ygyno.2009.04.019

    authors： Rocconi RP,Matthews KS,Kemper MK,Hoskins KE,Huh WK,Straughn JM Jr

    更新日期：2009-08-01 00:00:00

  • Neuropilin-1 promotes unlimited growth of ovarian cancer by evading contact inhibition.

    abstract：OBJECTIVE:Neuropilin-1 (NRP-1) is a receptor for both semaphorin and vascular endothelial growth factor and is up-regulated in a variety of human cancers. While there are some reports of NRP-1 expression in ovarian neoplasm, those results differ in pattern of its expression and its role in ovarian cancer is still uncle...

    journal_title：Gynecologic oncology

    pub_type： 杂志文章

    doi：10.1016/j.ygyno.2007.02.005

    authors： Baba T,Kariya M,Higuchi T,Mandai M,Matsumura N,Kondoh E,Miyanishi M,Fukuhara K,Takakura K,Fujii S

    更新日期：2007-06-01 00:00:00

  • Mucinous adenocarcinoma arising in rectovaginal fistulas associated with Crohn's disease.

    abstract：BACKGROUND:Crohn's disease is a chronic inflammatory disorder characterized by focal, transmural inflammation of the intestine. Gynecologic involvement, including rectovaginal fistula formation, is frequent. Case #1. A 53-year-old female with a 30-year history of Crohn's disease and numerous perirectal fistulas develop...

    journal_title：Gynecologic oncology

    pub_type： 杂志文章

    doi：10.1016/j.ygyno.2003.11.056

    authors： Moore-Maxwell CA,Robboy SJ

    更新日期：2004-04-01 00:00:00

  • BARD1, a possible biomarker for breast and ovarian cancer.

    abstract：:Breast cancer is the leading cause of cancer death in women. Ovarian cancer, although less frequent, is detected very late, and survival is correlated to early detection. Therefore, better methods for early detection would help to increase the number of survivors. The incidence of young women diagnosed with breast can...

    journal_title：Gynecologic oncology

    pub_type： 杂志文章,评审

    doi：10.1016/j.ygyno.2009.10.079

    authors： Irminger-Finger I

    更新日期：2010-05-01 00:00:00

  • Simple extrafascial trachelectomy and pelvic bilateral lymphadenectomy in early stage cervical cancer.

    abstract：OBJECTIVE:To determine the feasibility and safety of simple extra-fascial trachelectomy plus pelvic lymphadenectomy in young patients affected by early stage cervical cancer. METHODS:We have prospectively identified all patients with early-stage cervical cancer (stages IA2-IB1) referred to our department. Inclusion cr...

    journal_title：Gynecologic oncology

    pub_type： 临床试验,杂志文章

    doi：10.1016/j.ygyno.2012.04.004

    authors： Palaia I,Musella A,Bellati F,Marchetti C,Di Donato V,Perniola G,Benedetti Panici P

    更新日期：2012-07-01 00:00:00

  • Carboplatin and paclitaxel for advanced and recurrent cervical carcinoma: the British Columbia Cancer Agency experience.

    abstract：BACKGROUND:One of the most active chemotherapy combinations in advanced or recurrent cervical cancer is cisplatin-paclitaxel. However, this palliative regimen is associated with significant toxicity. Carboplatin-paclitaxel is thus an attractive option. METHODS:Patients with advanced or recurrent carcinoma of the cervi...

    journal_title：Gynecologic oncology

    pub_type： 杂志文章

    doi：10.1016/j.ygyno.2005.03.037

    authors： Tinker AV,Bhagat K,Swenerton KD,Hoskins PJ

    更新日期：2005-07-01 00:00:00

  • Stage I uterine carcinosarcoma: Matched cohort analyses for lymphadenectomy, chemotherapy, and brachytherapy.

    abstract：OBJECTIVE:To determine if lymphadenectomy, chemotherapy and radiotherapy are associated with survival benefit among women with stage I uterine carcinosarcoma. METHODS:Women with stage I uterine carcinosarcoma (n=5614) were identified from the 1998-2013 National Cancer Data Base. Kaplan-Meier survival estimates and Cox...

    journal_title：Gynecologic oncology

    pub_type： 杂志文章

    doi：10.1016/j.ygyno.2017.01.010

    authors： Seagle BL,Kanis M,Kocherginsky M,Strauss JB,Shahabi S

    更新日期：2017-04-01 00:00:00

  • Biologic therapeutics and molecular profiling to optimize wound healing.

    abstract：:Non-healing wounds represent a significant cause of morbidity and mortality for a large portion of the adult population. Wounds that fail to heal are entrapped in a self-sustaining cycle of chronic inflammation leading to the destruction of the extracellular matrix. Among cancer patients, malnutrition, radiation, phys...

    journal_title：Gynecologic oncology

    pub_type： 杂志文章,评审

    doi：10.1016/j.ygyno.2008.07.052

    authors： Menke MN,Menke NB,Boardman CH,Diegelmann RF

    更新日期：2008-11-01 00:00:00

  • The effect of medroxyprogesterone acetate on angiogenesis in complex endometrial hyperplasia.

    abstract：OBJECTIVE:To evaluate the effect of orally administered medroxyprogesterone acetate upon angiogenesis in the myometrium of patients with complex endometrial hyperplasia. METHODS:Microvessel counts in the myometrium of consecutive patients with complex endometrial hyperplasia, treated with oral medroxyprogesterone acet...

    journal_title：Gynecologic oncology

    pub_type： 杂志文章

    doi：10.1006/gyno.1998.5106

    authors： Abulafia O,Triest WE,Adcock JT,Sherer DM

    更新日期：1999-02-01 00:00:00

  • Protease-activated receptor-2 (PAR-2) in cervical cancer proliferation.

    abstract：OBJECTIVE:Protease-activated receptor-2 (PAR-2) is a G-protein-coupled receptor that is cleaved and activated by trypsin and tryptase. There is evidence that PAR-2 contributes to tumor progression in stomach, colon, pancreas, prostate and breast cancer patients. However, the role of PAR-2 in cervical cancer is still un...

    journal_title：Gynecologic oncology

    pub_type： 杂志文章

    doi：10.1016/j.ygyno.2007.08.083

    authors： Sánchez-Hernández PE,Ramirez-Dueñas MG,Albarran-Somoza B,García-Iglesias T,del Toro-Arreola A,Franco-Topete R,Daneri-Navarro A

    更新日期：2008-01-01 00:00:00

  • Nibrin is a marker of clinical outcome in patients with advanced serous ovarian cancer treated in the phase III OVA-301 trial.

    abstract：OBJECTIVE:This study investigated the relationship between 13 proteins involved in DNA damage and the outcomes of patients with recurrent ovarian cancer (ROC). PATIENTS AND METHODS:Immunohistochemistry staining was performed in 114 diagnostic samples from patients with serous ROC who participated in the OVA-301 study,...

    journal_title：Gynecologic oncology

    pub_type： 杂志文章

    doi：10.1016/j.ygyno.2013.10.032

    authors： Monk BJ,Kaye SB,Poveda A,Herzog TJ,Aracil M,Nieto A,Badri N,Parekh TV,Tanović A,Galmarini CM

    更新日期：2014-01-01 00:00:00

  • Integration and safety of fertility preservation in a breast cancer program.

    abstract：:Young women diagnosed with breast cancer typically face systemic treatments that may delay childbearing or permanently impair their fertility. These concerns add to the stress experienced by young cancer survivors. Timely counseling and providing fertility preservation through cryopreservation of eggs or embryos have ...

    journal_title：Gynecologic oncology

    pub_type： 社论

    doi：10.1016/j.ygyno.2011.11.028

    authors： Westphal LM,Wapnir IL

    更新日期：2012-03-01 00:00:00

  • Fas-mediated pathway and apoptosis in normal, hyperplastic, and neoplastic endometrium.

    abstract：OBJECTIVES:Abnormalities in the control of cell proliferation and apoptosis have been suggested to contribute to the development and progression of neoplasia. There are at least two pathways that activate apoptosis. The first is a mitochondria-dependent route governed by bcl-2 family proteins. The second is a parallel ...

    journal_title：Gynecologic oncology

    pub_type： 杂志文章

    doi：10.1016/s0090-8258(03)00411-6

    authors： Atasoy P,Bozdoğan O,Erekul S,Bozdoğan N,Bayram M

    更新日期：2003-11-01 00:00:00

  • Risk-based stratification of carcinomas concurrently involving the endometrium and ovary.

    abstract：OBJECTIVE:Determining whether carcinomas concurrently involving endometrium and ovary are independent primary tumors (IPTs) or endometrial carcinomas with ovarian metastases (at least stage IIIA endometrial cancers, IIIA-EC) using clinicopathologic criteria is often challenging. Recent genomic studies showed that most ...

    journal_title：Gynecologic oncology

    pub_type： 杂志文章

    doi：10.1016/j.ygyno.2018.10.033

    authors： Turashvili G,Gómez-Hidalgo NR,Flynn J,Gonen M,Leitao MM Jr,Soslow RA,Murali R

    更新日期：2019-01-01 00:00:00